<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">ppan</journal-id><journal-title-group><journal-title xml:lang="en">Personalized Psychiatry and Neurology</journal-title><trans-title-group xml:lang="ru"><trans-title>Personalized Psychiatry and Neurology</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2712-9179</issn><publisher><publisher-name>V. M. Bekhterev National Medical Research Centre for Psychiatry and Neurology of the Ministry of Health of the Russian Federation (Bekhterev NMRC PN)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.52667/2712-9179-2022-2-1-4-21</article-id><article-id custom-type="elpub" pub-id-type="custom">ppan-36</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>LECTION</subject></subj-group></article-categories><title-group><article-title>Phase I of Antipsychotics Metabolism and its Pharmacogenetic Testing</article-title><trans-title-group xml:lang="ru"><trans-title></trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="western" xml:lang="en"><surname>Shnayder</surname><given-names>N. A.</given-names></name></name-alternatives><bio xml:lang="en"><p>Natalia A. Shnayder</p><p>192019 Saint Petersburg; 660022 Krasnoyarsk; Tel.: +7-(812)-670-02-2078-14</p></bio><email xlink:type="simple">naschnaider@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="western" xml:lang="en"><surname>Abdyrakhmanova</surname><given-names>A. K.</given-names></name></name-alternatives><bio xml:lang="en"><p>Aiperi K. Abdyrakhmanova</p><p>192019 Saint Petersburg; Tel.: +7-(812)-670-02-2078-14</p></bio><email xlink:type="simple">abdyrahmanova_peri@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="western" xml:lang="en"><surname>Nasyrova</surname><given-names>R. F.</given-names></name></name-alternatives><bio xml:lang="en"><p>Regina F. Nasyrova</p><p>192019 Saint Petersburg; 443099 Samara; Tel.: +7-(812)-670-02-2078-14</p></bio><email xlink:type="simple">nreginaf77@gmail.com</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff xml:lang="en" id="aff-1"><institution>Institute of Personalized Psychiatry and Neurology, Shared Core Facilities, V. M. Bekhterev National Medical Research Centre for Psychiatry and Neurology; Shared Core Facilities Molecular and Cell Technology, V. F. Voino-Yasenetsky Krasnoyarsk State Medical University</institution><country>Russian Federation</country></aff><aff xml:lang="en" id="aff-2"><institution>Institute of Personalized Psychiatry and Neurology, Shared Core Facilities, V. M. Bekhterev National Medical Research Centre for Psychiatry and Neurology</institution><country>Russian Federation</country></aff><aff xml:lang="en" id="aff-3"><institution>Institute of Personalized Psychiatry and Neurology, Shared Core Facilities, V. M. Bekhterev National Medical Research Centre for Psychiatry and Neurology; International Centre for Education and Research in Neuropsychiatry, Samara State Medical University</institution><country>Russian Federation</country></aff><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>15</day><month>05</month><year>2022</year></pub-date><volume>2</volume><issue>1</issue><fpage>4</fpage><lpage>21</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Shnayder N.A., Abdyrakhmanova A.K., Nasyrova R.F., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Shnayder N.A., Abdyrakhmanova A.K., Nasyrova R.F.</copyright-holder><copyright-holder xml:lang="en">Shnayder N.A., Abdyrakhmanova A.K., Nasyrova R.F.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.jppn.ru/jour/article/view/36">https://www.jppn.ru/jour/article/view/36</self-uri><abstract><p>Antipsychotics (APs) are a class of psychotrophic medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia but also in a range of other psychotic disorders. Biotransformation is a major mechanism for APs elimination. Most APs undergo biotransformation, or metabolism, after they enter the body. There are three phases of APs metabolism. Cytochrome P450 (CYP) monooxygenase (mixed function oxidase) plays a central role in the most APs biotransformation. CYP’s functional activity depends on gene-drug and drug-drug interaction and influences on occurrence of adverse drug reactions (ADRs). So, it is extremely important for a practicing psychiatrist to know the oxidation pathway of APs, since most of them are metabolized in the liver and this is important both to prevent ADRs and to avoid unwanted drug-drug interactions, which will undoubtedly increase the effectiveness and safety of AP therapy.</p></abstract><kwd-group xml:lang="en"><kwd>pharmacogenetics</kwd><kwd>personalized therapy</kwd><kwd>phase I</kwd><kwd>antipsychotics</kwd></kwd-group><funding-group><funding-statement xml:lang="en">This research received no external funding.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Finkel, R.; Clark, M.A., Cubeddu, L.X. Pharmacology, 4thed.; Lippincott Williams &amp; Wilkins: Philadeplphia, USA, 2008; pp. 151.</mixed-citation><mixed-citation xml:lang="en">Finkel, R.; Clark, M.A., Cubeddu, L.X. Pharmacology, 4thed.; Lippincott Williams &amp; Wilkins: Philadeplphia, USA, 2008; pp. 151.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Lally, J.; MacCabe, J.H. Antipsychotic medication in schizophrenia: a review. Br. Med. Bull. 2015, 114, 169–79. doi:10.1093/bmb/ldv017.</mixed-citation><mixed-citation xml:lang="en">Lally, J.; MacCabe, J.H. Antipsychotic medication in schizophrenia: a review. Br. Med. Bull. 2015, 114, 169–79. doi:10.1093/bmb/ldv017.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Grande, I.; Berk, M.; Birmaher, B.; Vieta, E. Bipolar disorder. Lancet 2016, 387, 1561–1572. doi:10.1016/S0140-6736(15)00241-X.</mixed-citation><mixed-citation xml:lang="en">Grande, I.; Berk, M.; Birmaher, B.; Vieta, E. Bipolar disorder. Lancet 2016, 387, 1561–1572. doi:10.1016/S0140-6736(15)00241-X.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Caroff, S. N.; Hurford, I.; Lybrand, J.; Campbell, E. C. Movement Disorders Induced by Antipsychotic Drugs: Implications of the CATIE Schizophrenia Trial. Neurol. Clin. 2011, 29, 127–148. doi:10.1016/j.ncl.2010.10.002.</mixed-citation><mixed-citation xml:lang="en">Caroff, S. N.; Hurford, I.; Lybrand, J.; Campbell, E. C. Movement Disorders Induced by Antipsychotic Drugs: Implications of the CATIE Schizophrenia Trial. Neurol. Clin. 2011, 29, 127–148. doi:10.1016/j.ncl.2010.10.002.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Sadock, B. J.; Sadock, V.A.; Ruiz, P. Kaplan and Sadock's Comprehensive Textbook of Psychiatry, 9th ed.; Lippincott Williams &amp; Wilkins: Philadeplphia, USA, 2009; pp. 4113-4119.</mixed-citation><mixed-citation xml:lang="en">Sadock, B. J.; Sadock, V.A.; Ruiz, P. Kaplan and Sadock's Comprehensive Textbook of Psychiatry, 9th ed.; Lippincott Williams &amp; Wilkins: Philadeplphia, USA, 2009; pp. 4113-4119.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Meltzer, H.Y. Update on typical and atypical antipsychotic drugs. An. Rev. Med. 2013, 64, 393-406. doi:10.1146/annurev-med050911-161504.</mixed-citation><mixed-citation xml:lang="en">Meltzer, H.Y. Update on typical and atypical antipsychotic drugs. An. Rev. Med. 2013, 64, 393-406. doi:10.1146/annurev-med050911-161504.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Sheehan, J.J.; Sliwa, J.K.; Amatniek, J.C.; Grinspan, A.; Canuso, C.M. Atypical antipsychotic metabolism and excretion. Curr. Drug Metab. 2010, 11, 516-25. doi:10.2174/138920010791636202.</mixed-citation><mixed-citation xml:lang="en">Sheehan, J.J.; Sliwa, J.K.; Amatniek, J.C.; Grinspan, A.; Canuso, C.M. Atypical antipsychotic metabolism and excretion. Curr. Drug Metab. 2010, 11, 516-25. doi:10.2174/138920010791636202.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Rourke, J. L.; Sinal, C. J. Biotransformation/Metabolism. Encyclop. Toxic. 2014, 1, 490–502. doi:10.1016/b978-0-12-386454-3.00007-5.</mixed-citation><mixed-citation xml:lang="en">Rourke, J. L.; Sinal, C. J. Biotransformation/Metabolism. Encyclop. Toxic. 2014, 1, 490–502. doi:10.1016/b978-0-12-386454-3.00007-5.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Shanu-Wilson, J.; Evans, L.; Wrigley, S.; Steele, J.; Atherton, J.; Boer, J. (2020). Biotransformation: Impact and Application of Metabolism in Drug Discovery. ACS Med. Chem. Lett. 2020, 11, 2087-2107. doi:10.1021/acsmedchemlett.0c0020.</mixed-citation><mixed-citation xml:lang="en">Shanu-Wilson, J.; Evans, L.; Wrigley, S.; Steele, J.; Atherton, J.; Boer, J. (2020). Biotransformation: Impact and Application of Metabolism in Drug Discovery. ACS Med. Chem. Lett. 2020, 11, 2087-2107. doi:10.1021/acsmedchemlett.0c0020.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Shen, W. W. The Metabolism of Atypical Antipsychotic Drugs: An Update. Ann. Clin. Psychiatry 1999, 11, 145–158. doi:10.1023/a:1022312111429.</mixed-citation><mixed-citation xml:lang="en">Shen, W. W. The Metabolism of Atypical Antipsychotic Drugs: An Update. Ann. Clin. Psychiatry 1999, 11, 145–158. doi:10.1023/a:1022312111429.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Correia M.A. Drug biotransformation. In Basic &amp; Clinical Pharmacology, 14th ed.; Katzung, B.G.; McGraw Hill Education: New York, USA, 2017; Volume 1, pp. 56–74.</mixed-citation><mixed-citation xml:lang="en">Correia M.A. Drug biotransformation. In Basic &amp; Clinical Pharmacology, 14th ed.; Katzung, B.G.; McGraw Hill Education: New York, USA, 2017; Volume 1, pp. 56–74.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Josephy, D.P.; Guengerich, P.F.; Miners, J.O. “Phase I and Phase II” drug metabolism: terminology that we should phase out? Drug metab. Rev. 2005, 37, 575-580. doi: 10.1080/03602530500251220.</mixed-citation><mixed-citation xml:lang="en">Josephy, D.P.; Guengerich, P.F.; Miners, J.O. “Phase I and Phase II” drug metabolism: terminology that we should phase out? Drug metab. Rev. 2005, 37, 575-580. doi: 10.1080/03602530500251220.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Guengerich, F.P. (June 2001). Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem. Res. Toxicol. 2001, 14, 611–50 doi:10.1021/tx0002583.</mixed-citation><mixed-citation xml:lang="en">Guengerich, F.P. (June 2001). Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem. Res. Toxicol. 2001, 14, 611–50 doi:10.1021/tx0002583.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Bachmann, K. Drug Metabolism. Pharmacology 2009, 8, 131–173. doi:10.1016/b978-0-12-369521-5.00008-7.</mixed-citation><mixed-citation xml:lang="en">Bachmann, K. Drug Metabolism. Pharmacology 2009, 8, 131–173. doi:10.1016/b978-0-12-369521-5.00008-7.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Beedham, C. The role of non-P450 enzymes in drug oxidation. Pharm. World Sci. 1997, 19, 255–263. doi:10.1023/a:1008668913093.</mixed-citation><mixed-citation xml:lang="en">Beedham, C. The role of non-P450 enzymes in drug oxidation. Pharm. World Sci. 1997, 19, 255–263. doi:10.1023/a:1008668913093.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Manikandan, P.; Nagini S. Cytochrome P450 Structure, Function and Clinical Significance: A Review. Curr. Drug Targets 2018, 19, 38-54. doi: 10.2174/1389450118666170125144557.</mixed-citation><mixed-citation xml:lang="en">Manikandan, P.; Nagini S. Cytochrome P450 Structure, Function and Clinical Significance: A Review. Curr. Drug Targets 2018, 19, 38-54. doi: 10.2174/1389450118666170125144557.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Danielson, P.B. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Cur. Drug Metab. 2002, 3, 561–97. doi:10.2174/1389200023337054.</mixed-citation><mixed-citation xml:lang="en">Danielson, P.B. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Cur. Drug Metab. 2002, 3, 561–97. doi:10.2174/1389200023337054.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Pandey, A.V.; Flück, C.E. NADPH P450 oxidoreductase: structure, function, and pathology of diseases. Pharmacol. Ther. 2013, 138, 229–54. doi:10.1016/j.pharmthera.2013.01.010.</mixed-citation><mixed-citation xml:lang="en">Pandey, A.V.; Flück, C.E. NADPH P450 oxidoreductase: structure, function, and pathology of diseases. Pharmacol. Ther. 2013, 138, 229–54. doi:10.1016/j.pharmthera.2013.01.010.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Jensen, K.; Møller, B.L. Plant NADPH-cytochrome P450 oxidoreductases. Phytochemistry 2010, 71, 132–41. doi:10.1016/j.phytochem.2009.10.017.</mixed-citation><mixed-citation xml:lang="en">Jensen, K.; Møller, B.L. Plant NADPH-cytochrome P450 oxidoreductases. Phytochemistry 2010, 71, 132–41. doi:10.1016/j.phytochem.2009.10.017.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Klein, M. T.; Torry, L. A.; Wu, B. C.; Townsend, S. H.; Paspek, S. C. Hydrolysis in supercritical water: Solvent effects as a probe of the reaction mechanism. Journ. Supercrit. Fluids 1990, 3, 222–227. doi:10.1016/0896-8446(90)90026-I.</mixed-citation><mixed-citation xml:lang="en">Klein, M. T.; Torry, L. A.; Wu, B. C.; Townsend, S. H.; Paspek, S. C. Hydrolysis in supercritical water: Solvent effects as a probe of the reaction mechanism. Journ. Supercrit. Fluids 1990, 3, 222–227. doi:10.1016/0896-8446(90)90026-I.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Jancova, P.; Anzenbacher, P.; Anzenbacherova E. Phase II drug metabolizing enzymes. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 2010, 154, 103-16. doi: 10.5507/bp.2010.017.</mixed-citation><mixed-citation xml:lang="en">Jancova, P.; Anzenbacher, P.; Anzenbacherova E. Phase II drug metabolizing enzymes. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 2010, 154, 103-16. doi: 10.5507/bp.2010.017.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Jancova, P.; Siller, M. Phase II Drug Metabolism. Top. Drug Metab. 2012. doi:10.5772/29996.</mixed-citation><mixed-citation xml:lang="en">Jancova, P.; Siller, M. Phase II Drug Metabolism. Top. Drug Metab. 2012. doi:10.5772/29996.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">McCarver, D. G. The Ontogeny of Human Drug-Metabolizing Enzymes: Phase II Conjugatio Enzymes and Regulatory Mechanisms. J. Pharmacol. Exp. Ther. 2002, 300, 361–366. doi:10.1124/jpet.300.2.361.</mixed-citation><mixed-citation xml:lang="en">McCarver, D. G. The Ontogeny of Human Drug-Metabolizing Enzymes: Phase II Conjugatio Enzymes and Regulatory Mechanisms. J. Pharmacol. Exp. Ther. 2002, 300, 361–366. doi:10.1124/jpet.300.2.361.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Al-Zoughool, M.; Talaska, G. 4-Aminobiphenyl N-glucuronidation by liver microsomes: optimization of the reaction conditions and characterization of the UDP-glucoronosyltransferase isoforms. J. Appl. Toxic 2006, 26, 524–532. doi:10.1002/jat.1172.</mixed-citation><mixed-citation xml:lang="en">Al-Zoughool, M.; Talaska, G. 4-Aminobiphenyl N-glucuronidation by liver microsomes: optimization of the reaction conditions and characterization of the UDP-glucoronosyltransferase isoforms. J. Appl. Toxic 2006, 26, 524–532. doi:10.1002/jat.1172.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Rosenfeld, G.C.; Loose, D.S. Pharmacology, 6th ed.; Lippincott Williams &amp; Wilkins: Philadeplphia, USA, 2013; pp. 12-15.</mixed-citation><mixed-citation xml:lang="en">Rosenfeld, G.C.; Loose, D.S. Pharmacology, 6th ed.; Lippincott Williams &amp; Wilkins: Philadeplphia, USA, 2013; pp. 12-15.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Omiecinski, C.J.; Vanden, Heuvel, J. P.; Perdew, G. H.; Peters, J. M. Xenobiotic Metabolism, Disposition, and Regulation by Receptors: From Biochemical Phenomenon to Predictors of Major Toxicities. Toxicol. Sci. 2010, 120, S49–S75. doi:10.1093/toxsci/kfq338.</mixed-citation><mixed-citation xml:lang="en">Omiecinski, C.J.; Vanden, Heuvel, J. P.; Perdew, G. H.; Peters, J. M. Xenobiotic Metabolism, Disposition, and Regulation by Receptors: From Biochemical Phenomenon to Predictors of Major Toxicities. Toxicol. Sci. 2010, 120, S49–S75. doi:10.1093/toxsci/kfq338.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Nelson, D.R. (January 2018). Cytochrome P450 diversity in the tree of life. Biochim. Biophys. Acta Proteins Proteom. 2018, 1866, 141–154. doi:10.1016/j.bbapap.2017.05.003.</mixed-citation><mixed-citation xml:lang="en">Nelson, D.R. (January 2018). Cytochrome P450 diversity in the tree of life. Biochim. Biophys. Acta Proteins Proteom. 2018, 1866, 141–154. doi:10.1016/j.bbapap.2017.05.003.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Nasyrova, R.F.; Neznanov, N.G. Pharmacogenetics of antipsychotics. In Clinical psychopharmacogenetics; Nasyrova, R.F.; Kravtsov, V.V.; Dobrodeeva, V.S.; Schneider, N.A.; Neznanov N.G. DEAN: Saint Petersburg, Russia, 2019; pp. 93-174 (in Russ.).</mixed-citation><mixed-citation xml:lang="en">Nasyrova, R.F.; Neznanov, N.G. Pharmacogenetics of antipsychotics. In Clinical psychopharmacogenetics; Nasyrova, R.F.; Kravtsov, V.V.; Dobrodeeva, V.S.; Schneider, N.A.; Neznanov N.G. DEAN: Saint Petersburg, Russia, 2019; pp. 93-174 (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Uno, Y.; Iwasaki, K.; Yamazaki, H.; Nelson, D. R. (2011). Macaque cytochromes P450: nomenclature, transcript, gene, genomic structure, and function. Drug. Metab. Rev. 2011, 43, 346–361. doi:10.3109/03602532.2010.549492.</mixed-citation><mixed-citation xml:lang="en">Uno, Y.; Iwasaki, K.; Yamazaki, H.; Nelson, D. R. (2011). Macaque cytochromes P450: nomenclature, transcript, gene, genomic structure, and function. Drug. Metab. Rev. 2011, 43, 346–361. doi:10.3109/03602532.2010.549492.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Thomas, L. P.; Laszlo, K. Rapid review pharmacology, 3rd ed.; Elsevier: Amsterdam, Netherlands, 2010; pp. 7-9.</mixed-citation><mixed-citation xml:lang="en">Thomas, L. P.; Laszlo, K. Rapid review pharmacology, 3rd ed.; Elsevier: Amsterdam, Netherlands, 2010; pp. 7-9.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Nelson, D.R. Cytochrome P450 Homepage. Hum. Genomics 2009, 4, 59-65. doi:10.1186/1479-7364-4-1-59.</mixed-citation><mixed-citation xml:lang="en">Nelson, D.R. Cytochrome P450 Homepage. Hum. Genomics 2009, 4, 59-65. doi:10.1186/1479-7364-4-1-59.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">The human protein atlas. Available online: https://www.proteinatlas.org/ (accessed on 15 January 2022).</mixed-citation><mixed-citation xml:lang="en">The human protein atlas. Available online: https://www.proteinatlas.org/ (accessed on 15 January 2022).</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Guengerich, F.P. Mechanisms of Cytochrome P450-Catalyzed Oxidations. ACS Catal. 2018, 7, 10964-10976. doi:10.1021/acscatal.8b03401.</mixed-citation><mixed-citation xml:lang="en">Guengerich, F.P. Mechanisms of Cytochrome P450-Catalyzed Oxidations. ACS Catal. 2018, 7, 10964-10976. doi:10.1021/acscatal.8b03401.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Rendic, S.; Di Carlo, F.J. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev. 1997, 29, 413-580. doi:10.3109/03602539709037591.</mixed-citation><mixed-citation xml:lang="en">Rendic, S.; Di Carlo, F.J. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev. 1997, 29, 413-580. doi:10.3109/03602539709037591.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Drugbak Online. Available online: https://go.drugbank.com/ (accessed on 18 January 2022).</mixed-citation><mixed-citation xml:lang="en">Drugbak Online. Available online: https://go.drugbank.com/ (accessed on 18 January 2022).</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Le, T.; Bhushan, V.; Sochat, M.; Vaidyanathan, V.; Schimansky, S.; Abrams, J.; Kallianos, K. First Aid for the USMLE Step 1, 30th ed.; McGraw Hill Education: New York, USA, 2020; pp. 252.</mixed-citation><mixed-citation xml:lang="en">Le, T.; Bhushan, V.; Sochat, M.; Vaidyanathan, V.; Schimansky, S.; Abrams, J.; Kallianos, K. First Aid for the USMLE Step 1, 30th ed.; McGraw Hill Education: New York, USA, 2020; pp. 252.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Hukkanen, J. Induction of cytochrome P450 enzymes: a view on human in vivo findings. Expert Rev. Clin. Pharmacol. 2012, 5, 569-85. doi: 10.1586/ecp.12.39.</mixed-citation><mixed-citation xml:lang="en">Hukkanen, J. Induction of cytochrome P450 enzymes: a view on human in vivo findings. Expert Rev. Clin. Pharmacol. 2012, 5, 569-85. doi: 10.1586/ecp.12.39.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Drug Interactions Flockhart Table. Available online: https://drug-interactions.medicine.iu.edu/MainTable.aspx (accessed on 18 January 2022).</mixed-citation><mixed-citation xml:lang="en">Drug Interactions Flockhart Table. Available online: https://drug-interactions.medicine.iu.edu/MainTable.aspx (accessed on 18 January 2022).</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Pond, S.M.; Tozer, T.N. First-pass elimination basic concepts and clinical consequences."Clin. Pharmacokinet. 1984, 9, 1-25. doi: 10.2165/00003088-198409010-00001.</mixed-citation><mixed-citation xml:lang="en">Pond, S.M.; Tozer, T.N. First-pass elimination basic concepts and clinical consequences."Clin. Pharmacokinet. 1984, 9, 1-25. doi: 10.2165/00003088-198409010-00001.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Rowland, M.; Benet, L.Z.; Graham, G.G. Clearance concepts in pharmacokinetics. J. Pharmacokinet. Biopharm. 1973, 1, 123-136. doi: 10.1007/BF01059626.</mixed-citation><mixed-citation xml:lang="en">Rowland, M.; Benet, L.Z.; Graham, G.G. Clearance concepts in pharmacokinetics. J. Pharmacokinet. Biopharm. 1973, 1, 123-136. doi: 10.1007/BF01059626.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Inger, J.; Mangus, I.S. Genetic polymorphism and toxicology--with emphasis on cytochrome p450. Toxicol. Sci. 2011, 120, 1-13. doi: 10.1093/toxsci/kfq374.</mixed-citation><mixed-citation xml:lang="en">Inger, J.; Mangus, I.S. Genetic polymorphism and toxicology--with emphasis on cytochrome p450. Toxicol. Sci. 2011, 120, 1-13. doi: 10.1093/toxsci/kfq374.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Werk, A.N.; Cascorbi, I. Functional gene variants of CYP3A4. Clin. Pharmacol. Ther. 2014, 96, 340-8. doi: 10.1038/clpt.2014.129.</mixed-citation><mixed-citation xml:lang="en">Werk, A.N.; Cascorbi, I. Functional gene variants of CYP3A4. Clin. Pharmacol. Ther. 2014, 96, 340-8. doi: 10.1038/clpt.2014.129.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">US Food and Drug Administration. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available online: https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substratesinhibitors-and-inducers (accessed on 20 January 2022).</mixed-citation><mixed-citation xml:lang="en">US Food and Drug Administration. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available online: https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substratesinhibitors-and-inducers (accessed on 20 January 2022).</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">US Food and Drug Administration. Clinical drug interaction studies — Cytochrome P450 enzyme- and transporter-mediated drug interactions guidance for industry, January 2020. Available online: https://www.fda.gov/regulatory-information/search-fdaguidance-documents/clinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions (accessed on 20 January 2022).</mixed-citation><mixed-citation xml:lang="en">US Food and Drug Administration. Clinical drug interaction studies — Cytochrome P450 enzyme- and transporter-mediated drug interactions guidance for industry, January 2020. Available online: https://www.fda.gov/regulatory-information/search-fdaguidance-documents/clinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions (accessed on 20 January 2022).</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Fluphenazine: Drug information. Available online: https://www.uptodate.com/contents/fluphenazine-drug-information?topicRef=14773&amp;source=see_link (accessed on 20 January 2022).</mixed-citation><mixed-citation xml:lang="en">Fluphenazine: Drug information. Available online: https://www.uptodate.com/contents/fluphenazine-drug-information?topicRef=14773&amp;source=see_link (accessed on 20 January 2022).</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Pimozide: Drug information. Available online: https://www.uptodate.com/contents/pimozide-drug-information?topicRef=14773&amp;source=see_link (accessed on 20 January 2022).</mixed-citation><mixed-citation xml:lang="en">Pimozide: Drug information. Available online: https://www.uptodate.com/contents/pimozide-drug-information?topicRef=14773&amp;source=see_link (accessed on 20 January 2022).</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Stimmel, G.L.; Falloon, I.R. Chlorpromazine plasma levels, adverse effects, and tobacco smoking: case report. Clin. Psychiatry 198, 44, 420.</mixed-citation><mixed-citation xml:lang="en">Stimmel, G.L.; Falloon, I.R. Chlorpromazine plasma levels, adverse effects, and tobacco smoking: case report. Clin. Psychiatry 198, 44, 420.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Pantuck, E. J.; Pantuck, C. B.; Anderson, K. E.; Conney, A. H.; Kappas, A. Cigarette smoking and chlorpromazine disposition and actions. Clin. Pharmacol. Ther. 1982, 31, 533–538. doi:10.1038/clpt.1982.72</mixed-citation><mixed-citation xml:lang="en">Pantuck, E. J.; Pantuck, C. B.; Anderson, K. E.; Conney, A. H.; Kappas, A. Cigarette smoking and chlorpromazine disposition and actions. Clin. Pharmacol. Ther. 1982, 31, 533–538. doi:10.1038/clpt.1982.72</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Ereshefsky, L.; Saklad, S.R.; Watanabe, M.D.; Davis, C.M.; Jann, M.W . Thiothixene pharmacokinetic interactions: a study of hepatic enzyme inducers, clearance inhibitors, and demographic variables. J. Clin. Psychopharmacol. 1991, 11, 296.</mixed-citation><mixed-citation xml:lang="en">Ereshefsky, L.; Saklad, S.R.; Watanabe, M.D.; Davis, C.M.; Jann, M.W . Thiothixene pharmacokinetic interactions: a study of hepatic enzyme inducers, clearance inhibitors, and demographic variables. J. Clin. Psychopharmacol. 1991, 11, 296.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Aripiprazole (oral and long-acting injectable [Abilify Maintena]): Drug information. Available online: https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-drug-information?topicRef=14776&amp;source=see_link (accessed on 20 January 2022).</mixed-citation><mixed-citation xml:lang="en">Aripiprazole (oral and long-acting injectable [Abilify Maintena]): Drug information. Available online: https://www.uptodate.com/contents/aripiprazole-oral-and-long-acting-injectable-abilify-maintena-drug-information?topicRef=14776&amp;source=see_link (accessed on 20 January 2022).</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Asenapine: Drug information. Available online: https://www.uptodate.com/contents/asenapine-drug-information?topicRef=14776&amp;source=see_link (accessed on 20 January 2022).</mixed-citation><mixed-citation xml:lang="en">Asenapine: Drug information. Available online: https://www.uptodate.com/contents/asenapine-drug-information?topicRef=14776&amp;source=see_link (accessed on 20 January 2022).</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Rexulti (brexpiprazole): Otsuka America Pharmaceutical, Inc. 2015. http://www.otsuka-us.com/Products/Documents/Rexulti.PI.pdf (accessed on 20 January 2022).</mixed-citation><mixed-citation xml:lang="en">Rexulti (brexpiprazole): Otsuka America Pharmaceutical, Inc. 2015. http://www.otsuka-us.com/Products/Documents/Rexulti.PI.pdf (accessed on 20 January 2022).</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Citrome, L.; Stensbøl, T.B.; Maeda, K. The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders? Expert. Rev. Neurother. 2015,15, 1219-29.</mixed-citation><mixed-citation xml:lang="en">Citrome, L.; Stensbøl, T.B.; Maeda, K. The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders? Expert. Rev. Neurother. 2015,15, 1219-29.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">U.S. Food and Drug Administration Safety Communication: Vraylar Package Insert. Available online: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204370lbl.pdf (accessed on 20 January 2022).</mixed-citation><mixed-citation xml:lang="en">U.S. Food and Drug Administration Safety Communication: Vraylar Package Insert. Available online: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204370lbl.pdf (accessed on 20 January 2022).</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Clozaril (clozapine): Novartis, Inc. 2014. Available online: https://www.pharma.us.novartis.com/product/pi/pdf/Clozaril.pdf (accessed on 20 January 2022).</mixed-citation><mixed-citation xml:lang="en">Clozaril (clozapine): Novartis, Inc. 2014. Available online: https://www.pharma.us.novartis.com/product/pi/pdf/Clozaril.pdf (accessed on 20 January 2022).</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Anderson, G.D.; Chan, L.N. Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products. Clin. Pharmacokinet. 2016, 55, 1353-1368. doi: 10.1007/s40262-016-0400-9.</mixed-citation><mixed-citation xml:lang="en">Anderson, G.D.; Chan, L.N. Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products. Clin. Pharmacokinet. 2016, 55, 1353-1368. doi: 10.1007/s40262-016-0400-9.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Fanapt (iloperidone): Vanda Pharmaceutical, Inc. 2014. Available online: https://www.fanapt.com/product/pi/pdf/fanapt.pdf (accessed on 20 January 2022).</mixed-citation><mixed-citation xml:lang="en">Fanapt (iloperidone): Vanda Pharmaceutical, Inc. 2014. Available online: https://www.fanapt.com/product/pi/pdf/fanapt.pdf (accessed on 20 January 2022).</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Lumateperone: Drug information. Available online: https://www.uptodate.com/contents/lumateperone-drug-information?topicRef=14776&amp;source=see_link (accessed on 20 January 2022).</mixed-citation><mixed-citation xml:lang="en">Lumateperone: Drug information. Available online: https://www.uptodate.com/contents/lumateperone-drug-information?topicRef=14776&amp;source=see_link (accessed on 20 January 2022).</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Latuda (lurasidone): Sunovion Pharmaceuticals, Inc. 2013. Available online: http://www.latuda.com/LatudaPrescribingInformation.pdf (accessed on 20 January 2022).</mixed-citation><mixed-citation xml:lang="en">Latuda (lurasidone): Sunovion Pharmaceuticals, Inc. 2013. Available online: http://www.latuda.com/LatudaPrescribingInformation.pdf (accessed on 20 January 2022).</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Zyprexa (olanzapine). Eli Lilly and Company, Inc. 2015. Available online: http://pi.lilly.com/us/zyprexa-pi.pdf (accessed on 20 January 2022).</mixed-citation><mixed-citation xml:lang="en">Zyprexa (olanzapine). Eli Lilly and Company, Inc. 2015. Available online: http://pi.lilly.com/us/zyprexa-pi.pdf (accessed on 20 January 2022).</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Invega (paliperidone): Janssen Pharmaceuticals, Inc. 2014. Available online: http://www.invega.com/prescribing-information (accessed on 20 January 2022).</mixed-citation><mixed-citation xml:lang="en">Invega (paliperidone): Janssen Pharmaceuticals, Inc. 2014. Available online: http://www.invega.com/prescribing-information (accessed on 20 January 2022).</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Nuplazid (pimavanserin): Full prescribing information. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207318lbl.pdf (accessed on 20 January 2022).</mixed-citation><mixed-citation xml:lang="en">Nuplazid (pimavanserin): Full prescribing information. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207318lbl.pdf (accessed on 20 January 2022).</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Seroquel (quetiapine): AstraZeneca 2013. Available online: http://www1.astrazeneca-us.com/pi/seroquel.pdf (accessed on 20 January 2022).</mixed-citation><mixed-citation xml:lang="en">Seroquel (quetiapine): AstraZeneca 2013. Available online: http://www1.astrazeneca-us.com/pi/seroquel.pdf (accessed on 20 January 2022).</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Seroquel XR (quetiapine extended release): AstraZeneca 2013. Available online: http://www.azpicentral.com/seroquelxr/seroquelxr.pdf#page=1 (accessed on 20 January 2022).</mixed-citation><mixed-citation xml:lang="en">Seroquel XR (quetiapine extended release): AstraZeneca 2013. Available online: http://www.azpicentral.com/seroquelxr/seroquelxr.pdf#page=1 (accessed on 20 January 2022).</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Risperdal (risperidone): Janssen Pharmaceuticals, Inc. 2014. Available online: http://www.janssenpharmaceuticalsinc.com/assets/risperdal.pdf (accessed on 20 January 2022).</mixed-citation><mixed-citation xml:lang="en">Risperdal (risperidone): Janssen Pharmaceuticals, Inc. 2014. Available online: http://www.janssenpharmaceuticalsinc.com/assets/risperdal.pdf (accessed on 20 January 2022).</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Geodon (ziprasidone): Pfizer, Inc. 2014. Available online: http://labeling.pfizer.com/ShowLabeling.aspx?id=584 (accessed on 20 January 2022).</mixed-citation><mixed-citation xml:lang="en">Geodon (ziprasidone): Pfizer, Inc. 2014. Available online: http://labeling.pfizer.com/ShowLabeling.aspx?id=584 (accessed on 20 January 2022).</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Javaid, J.I. Clinical pharmacokinetics of antipsychotics. J. Clin. Pharmacol. 1994, 34, 286-295. doi: 10.1002/j.1552-4604.1994.tb01995.x.</mixed-citation><mixed-citation xml:lang="en">Javaid, J.I. Clinical pharmacokinetics of antipsychotics. J. Clin. Pharmacol. 1994, 34, 286-295. doi: 10.1002/j.1552-4604.1994.tb01995.x.</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Belle, D.J.; Singh, H. Genetic factors in drug metabolism. Am. Fam. Physician. 2008, 77, 1553-1560.</mixed-citation><mixed-citation xml:lang="en">Belle, D.J.; Singh, H. Genetic factors in drug metabolism. Am. Fam. Physician. 2008, 77, 1553-1560.</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Pouget, J.G.; Shams, T.A.; Tiwari, A.K.; Muller, D.J. Pharmacogenetics and outcome with antipsychotic drugs. Dialog. Clin. Neurosci 2014, 16, 555-66. doi: 10.31887/DCNS.2014.16.4/jpouget.</mixed-citation><mixed-citation xml:lang="en">Pouget, J.G.; Shams, T.A.; Tiwari, A.K.; Muller, D.J. Pharmacogenetics and outcome with antipsychotic drugs. Dialog. Clin. Neurosci 2014, 16, 555-66. doi: 10.31887/DCNS.2014.16.4/jpouget.</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Genesight test. Available online: https://genesight.com/ (accessed on 20 January 2022).</mixed-citation><mixed-citation xml:lang="en">Genesight test. Available online: https://genesight.com/ (accessed on 20 January 2022).</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">Genesept assay. Available online: https://www.dynacare.ca/corporate-clients/wellness-featured-services/mental-health-solution.aspx (accessed on 20 January 2022).</mixed-citation><mixed-citation xml:lang="en">Genesept assay. Available online: https://www.dynacare.ca/corporate-clients/wellness-featured-services/mental-health-solution.aspx (accessed on 20 January 2022).</mixed-citation></citation-alternatives></ref><ref id="cit72"><label>72</label><citation-alternatives><mixed-citation xml:lang="ru">The human protein atlas: CYP1A1. Available online: https://www.proteinatlas.org/ENSG00000140465-CYP1A1/tissue (accessed on 20 January 2022).</mixed-citation><mixed-citation xml:lang="en">The human protein atlas: CYP1A1. Available online: https://www.proteinatlas.org/ENSG00000140465-CYP1A1/tissue (accessed on 20 January 2022).</mixed-citation></citation-alternatives></ref><ref id="cit73"><label>73</label><citation-alternatives><mixed-citation xml:lang="ru">Shnayder, N.A.; Abdyrakhmanova, A.K.; Nasyrova, R.F. Oxidation of Antipsychotics. Encyclopedia 2022, 2.</mixed-citation><mixed-citation xml:lang="en">Shnayder, N.A.; Abdyrakhmanova, A.K.; Nasyrova, R.F. Oxidation of Antipsychotics. Encyclopedia 2022, 2.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
